Gilead reports final outcomes from trial of bulevirtide for chronic HDV

Gilead Sciences has reported final outcomes from the Phase III MYR301 trial, indicating adults with chronic hepatitis delta virus (HDV), when treated with the entry inhibitor bulevirtide, could maintain virologic suppression nearly two years following treatment cessation post-achieving undetectable HDV RNA at end of treatment (EOT).